Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer Clinical research trials and Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer. Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "O" Clinical Trials Conditions > Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer



Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

For Condition: unspecified adult solid tumor, protocol specific
Status: Recruiting
Sponsor(s): Kaplan Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy such as oxaliplatin use different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth. Combining oxaliplatin with bortezomib may kill more cancer cells. PURPOSE: Phase I trial to study the effect on the body of combining oxaliplatin with bortezomib in treating patients who have metastatic or unresectable cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose and recommended phase II dose of oxaliplatin and bortezomib in patients with advanced malignancy. - Determine the dose-limiting toxicity of this regimen in these patients. - Determine the toxicity profile of this regimen in these patients. - Determine the antitumor activity of this regimen in these patients. - Determine the pattern of neurotoxicity and its reversibility in patients responding to prolonged administration of this treatment regimen. - Determine whether the pharmacokinetics and pharmacodynamics of oxaliplatin or bortezomib are altered by the administration of the other agent in these patients. OUTLINE: This is a dose-escalation study. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the maximum tolerated doses (MTDs) are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed for at least 3 months. PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 4-15 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignancy for which standard curative or palliative measures do not exist or are no longer effective - Metastatic or unresectable disease - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - More than 6 months Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin normal - AST and ALT no greater than 5 times upper limit of normal Renal - Creatinine no greater than 1.5 mg/dL Cardiovascular - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergic reactions attributed to compounds of similar chemical or biological composition to any platinum or other study agents - No pre-existing peripheral neuropathy - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance - No other concurrent uncontrolled illness PRIOR CONCURRENT THERAPY: Biologic therapy - Prior thalidomide allowed provided patient has no clinical neuropathy Chemotherapy - Prior platinum or antitubulin agents allowed provided patient has no clinical neuropathy - At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered Endocrine therapy - Not specified Radiotherapy - More than 3 weeks since prior radiotherapy and recovered Surgery - Not specified Other - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational or commercial agents or therapies for the malignancy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
HowardHochster,  Principal Investigator,  Kaplan Cancer Center

NYU School of Medicine's Kaplan Comprehensive Cancer Center *Recruiting*
New York City,  New York,  10016
United States
Recruiting Howard  Hochster 212-652-1912


Additional Information:
Study ID Numbers:  CDR0000316444;  NYU-0212,NCI-5736
Study Start Date: 
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00066625

Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Chemotherapy in Treating Patients With Solid Tumors

2. BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

3. Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

4. Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors

5. Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer

Related Studies:

Other unspecified adult solid tumor, protocol specific Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
Modify your Search

  Other unspecified adult solid tumor, protocol specific Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103